The FDA approved Sucampo s supplemental
Selected Abstract
The FDA approved Sucampo's supplemental NDA for Amitiza to treat irritable bowel syndrome with constipation in women 18 years of age or older.(Pipeline)
The FDA approved Sucampo's supplemental NDA for Amitiza to treat irritable bowel syndrome with constipation in women 18 years of age or older. As a result of the approval, Sucampo will receive a development milestone payment of $50 million from Takeda in accordance to a prior licensing agreement. ... June 1, 2008; Medical Marketing & Media
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
The FDA approved Sucampo's supplemental NDA for Amitiza to treat irritable bowel syndrome with constipation in women 18 years of age or older.(Pipeline)
|
